NOACs slow cognitive decline in Alzheimer’s patients with atrial fibrillation
They publishedThese blood thinners may have an unexpected benefit for Alzheimer’s patients
First reportScienceDaily · 18 Sept, 09:48Z
Latest reportScienceDaily · 18 Sept, 09:48Z
Span0 hours · two reports
Base — every candidate starts here5
Public-interest topic (politics, world, science, health…)+1
Public-interest terms in the text (courts, tariffs, ceasefire…)+1.25
High-reliability source boost+0.75
Significance8
Deterministic and identical for every story — no engagement signals, no personalization of the score.
Why it matters
What
A Karolinska study linked NOAC use to about 0.2 points less annual MMSE decline than warfarin or no anticoagulant.
Why
NOACs were also associated with lower risks of death, stroke, clots, and fractures among patients with atrial fibrillation and Alzheimer’s.
Watch
The observational study cannot prove causation, so further research should assess potential confounders and whether NOACs directly slow cognitive decline.
Where the coverage comes from
Perspective mix: 1 center.
Lean and credibility are curated v1 mappings from public ratings (AllSides / MBFC); unknown outlets stay unrated, never guessed. How outlets are rated →
How it unfolded — every article
Summary
- Karolinska Institutet study analyzed 7,308 patients with atrial fibrillation and Alzheimer’s.
- Participants were grouped to NOACs, warfarin, or no anticoagulant treatment.
- NOACs slowed MMSE decline by about 0.2 points per year versus others.
- NOACs also linked to lower risks of death, stroke, clots, and fractures.
- Study notes observational design and cannot prove causation; potential confounders exist.